PMN beat EPS expectations by 92.93%
Mar 31, 2025, 10:33 PM
0.00%
What does PMN do
ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
ProMIS Neurosciences (PMN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, ProMIS Neurosciences's actual EPS was -$0.01, beating the estimate of -$0.14 per share, resulting in a 92.93% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.